Related Experiment Video
Updated: Mar 11, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
10.2K
Pharmacologic progress in higher-risk MDS: an uphill battle
1Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA.
Expert Opinion on Pharmacotherapy
|March 10, 2026
Summary
Higher-risk myelodysplastic syndromes (MDS) are challenging to treat, with current therapies showing limited efficacy. Investigational treatments have faced difficulties in phase III trials, highlighting the need for better therapeutic strategies.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myelodysplastic syndromes (MDS) are clonal myeloid malignancies with ineffective hematopoiesis and risk of acute myeloid leukemia (AML).
- Higher-risk MDS remains largely incurable without stem cell transplantation.
- Current management relies on hypomethylating agents with modest efficacy.
Purpose of the Study:
- To review the history and evolution of investigational pharmacotherapy in higher-risk MDS.
- To identify challenges in translating early-phase trial successes to phase III trials.
- To inform future therapeutic breakthroughs in MDS treatment.
Main Methods:
- Review of historical and current investigational pharmacotherapy for higher-risk MDS.
- Analysis of clinical trial outcomes, focusing on phase III failures.
- Examination of molecular profiling and next-generation sequencing advancements.
Main Results:
- Despite advances in molecular profiling, targeted therapies in higher-risk MDS are limited.
- Numerous early-phase trials show promise, but phase III trials frequently fail.
- Biological complexity, heterogeneity, and trial design challenges contribute to failures.
Conclusions:
- Translating early successes of investigational therapies in higher-risk MDS to phase III trials remains a significant hurdle.
- Further understanding of MDS biology and improved trial designs are crucial for future therapeutic advancements.
- Development of novel and effective treatments for higher-risk MDS is urgently needed.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
01:28Drug Therapy
361
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
361
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59